Ones To Watch News
Refine Search
Biotechnology
Shares of US clinical-stage biotech C4 Therapeutics closed up a massive 98% on Tuesday and gained a further 12.8% to $2.64 pre-market, after the company announced a potentially lucrative deal with US pharma giant Merck & Co. 13 December 2023
Biotechnology
Californian antibody specialist Electra Therapeutics has appointed Kathy Dong as president and chief executive, replacing current CEO Adam Rosenthal. 13 December 2023
Biotechnology
Spanish dermatology specialist Almirall and etherna, a privately-held Belgian mRNA/lipid nanoparticle (LNP) technology platform company, have announced a collaboration. 12 December 2023
Biotechnology
The US Federal Trade Commission (FTC) is seeking to block French pharma major Sanofi’s proposed acquisition of an exclusive license to Maze Therapeutics therapy in development for treatment of Pompe disease. 12 December 2023
Biotechnology
Shares of USA-based Skye Bioscience rose 14% to $3.99 by mid-morning, after it revealed its intent to enter the huge and fast-growing obesity treatment sector. 11 December 2023
Pharmaceutical
Privately-held Swiss drugmaker Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome have announced a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. 11 December 2023
Biotechnology
The US Food and Drug Administration (FDA) on Friday approved two milestone treatments, Casgevy (exagamglogene autotemcel [exa-cel]), and Lyfgenia (lovotibeglogene autotemcel [lovo-cel)], representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD). 11 December 2023
Biotechnology
Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the appointment of Angèle Maki, as chief business officer (CBO), with immediate effect. 11 December 2023
Biotechnology
Shares of Intensity Therapeutics skyrocketed 120% to $8.79 pre-market today, after it announced positive safety, tolerability, efficacy and immune activation data from the company’s Phase II INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer. 9 December 2023
Biotechnology
German biotech BioNTech revealed that it has signed a multi-year strategic partnership with the State of Victoria in Australia to strengthen the local mRNA ecosystem and facilitate innovations deriving from it. 8 December 2023
Pharmaceutical
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, announced today that it has appointed Rayna Sethi Herman as chief commercial officer. 8 December 2023
Pharmaceutical
Since the US Food and Drug Administration’s acceptance of Madrigal Pharmaceutical’s new drug application (NDA) and priority review for its THR-β agonist (resmetirom) in non-alcoholic steatohepatitis (NASH) in September 2023, the company has taken steps to fortify its leadership and financial position to gear up for the imminent launch of resmetirom. 7 December 2023
Pharmaceutical
US hematology company Syros Pharmaceuticals has announced “strong and encouraging” initial data from its ongoing mid-stage trial, SELECT-AML-1. 7 December 2023
Biotechnology
Oncolytic immunotherapy company Replimune Group has announced results from the primary analysis of the CERPASS trial. 7 December 2023
Biotechnology
Texas, USA-based Coya Therapeutics saw its shares rise 2.5% to $7.46, on news of deal with India’s Dr Reddy’s Laboratories. 6 December 2023
Biotechnology
Ireland and USA-based natural killer (NK) cell therapy biotech ONK Therapeutics and US firm NAYA Biosciences have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. 6 December 2023
Biotechnology
Massachusetts, USA-based cell therapy specialist Abcuro today announced the appointment of Mark Pruzanski as chairman of its board of directors. 6 December 2023
Biotechnology
Germany-based Thermosome, a drug development company specializing in targeted tumor therapies, has named Frank Hermann as chief medical officer (CMO). 5 December 2023
Pharmaceutical
USA-based ophthalmic diseases specialist EyePoint Pharmaceuticals saw its shares leap as much as 212% yesterday, after it announced positive top-line results of its Phase II DAVIO 2 trial of EYP-1901. 5 December 2023
Biotechnology
Shares of UK-based cancer and women’s health drug developer ValiRx were up 16.6% at 11.51 pence mid-afternoon, following the announcement that its joint venture company ValiSeek has entered a deal to license VAL401 to Ambrose Healthcare 5 December 2023
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze